Summary: Researchers developed a closed-loop deep brain stimulation (DBS) system that reads and responds to human walking patterns in real time. While conventional DBS delivers a rigid, unyielding wave of electricity that frequently fails to resolve disabling Parkinson’s symptoms like freezing of gait and catastrophic falls, this new adaptive DBS (aDBS) system operates entirely within the sub-second timeline of human locomotion.
By embedding predictive neural algorithms directly into an implanted neurostimulator, the device tracks the individual electrical signatures of the left and right legs during each phase of stride execution. Operating autonomously without an external computer, the implant alters its therapeutic output within fractions of a second, acting as an intelligent “brain pacemaker” that works in perfect synchrony with the moving patient.
Key Facts
- The Stride-by-Stride Pacemaker Analog: Moving past outdated medical hardware models, the UCSF device operates precisely like a modern cardiac pacemaker. Instead of tracking the natural rhythm of the heart, the artificial intelligence architecture continuously monitors the brain’s unique rhythm of walking to calculate stimulation bursts.
- The Failure of Continuous Stimulation: Over ten million people worldwide live with Parkinson’s disease. While traditional continuous deep brain stimulation excels at suppressing tremors and stiffness, it remains largely ineffective against gait impairment, leaving patients highly vulnerable to wheel-chair dependency and traumatic fall injuries.
- The Bilateral Left-Right Neural Map: Dr. Wang’s team achieved a major engineering breakthrough by isolating the exact, individualized neural signatures generated when a patient lifts and plants their left or right foot. These data loops are loaded onto the embedded chip to handle step-by-second micro-adjustments.
- Laboratory and Real-World Validation: In controlled laboratory settings, the aDBS protocol triggered immediate improvements in spatial gait symmetry and slashed structural walking pattern variability. Subsequent multi-day, blinded crossover trials conducted in participants’ everyday home environments confirmed a massive reduction in physical falls.
- The Dual Cortical-Subcortical Array: To read and write behavior simultaneously, the five clinical trial participants were fitted with an advanced investigational array. In addition to deep subcortical brain stimulation leads, research electrodes were placed directly over movement-related cortical areas to capture clean intentional signals.
- A Paradigm Shift Toward Behavioral Feedback: Historically, adaptive neurotherapies have responded exclusively to slow-moving biological state changes, like medication tracking or overnight sleep cycles. The UCSF approach marks a profound shift by tying neural stimulation directly to active, millisecond behavior.
- The Future of Personalized Neuromodulation: Because this architecture proves the brain can dynamically listen and react to real-time actions, neurosurgeons project this framework will quickly scale to build responsive, personalized therapies for speech disorders, deep treatment-resistant depression, and cognitive decay.
Source: UCSF
UC San Francisco researchers have developed a new form of deep brain stimulation (DBS) that adjusts in real time as a person walks, helping improve gait and reduce falls in people with Parkinson’s disease.
The study, publishing June 15 in Nature Medicine, demonstrates for the first time that an implanted brain stimulator can detect neural signals associated with each step and automatically adjust stimulation within fractions of a second. Much like a cardiac pacemaker responds to the heart’s rhythm, the new system responds to the brain’s rhythm of walking.
“Difficulty walking is one of the most disabling symptoms of Parkinson’s disease and one of the hardest to treat,” said Doris D. Wang, MD, PhD, associate professor of neurological surgery at UCSF and senior author of the study. “Walking is a highly dynamic behavior that requires precise timing across both sides of the body. We developed a system that can recognize those movement patterns and respond in real time, effectively allowing the stimulation to work with the patient as they move.”
A Smarter Kind of Brain Stimulation
More than 10 million people worldwide live with Parkinson’s disease. While deep brain stimulation can dramatically improve tremor, stiffness, and slowness, many patients continue to struggle with gait impairment, freezing of gait, and falls —symptoms that are among the leading causes of disability and loss of independence.
The UCSF team believed that one reason standard DBS has limited effects on walking is that gait itself is constantly changing. Every step requires rapid coordination between the brain, spinal cord, and muscles. Conventional or continuous DBS, however, delivers a fixed pattern of stimulation regardless of what a person is doing.
To address this challenge, the researchers developed a personalized adaptive DBS (aDBS) system that identifies brain signals associated with movement of the left and right legs. These signals are then embedded directly into the implanted neurostimulator, allowing the device to automatically adjust stimulation during each phase of walking without requiring an external computer.
“The brain contains remarkably rich information about movement,” said first author Kenneth H. Louie, PhD, a UCSF post-doctoral scholar. “We found that we could identify neural signatures linked to each step and use them to guide stimulation in real time.”
From Constant Therapy to Responsive Therapy
The study enrolled five people with Parkinson’s disease who had undergone DBS surgery and were participating in a UCSF research program using an investigational DBS system. In addition to their therapeutic DBS leads implanted deep within the brain, participants had research electrodes placed over movement-related areas of the brain. Together, these devices allowed researchers to identify personalized neural signatures (brain signals) of walking and program the stimulator to automatically adjust therapy in real time.
In laboratory testing, the aDBS system improved measures of gait symmetry and reduced variability in walking patterns, both markers of more stable and efficient gait.
Participants then completed a blinded, multi-day crossover study in their daily lives. During periods when the adaptive system was active, participants experienced fewer falls while maintaining overall control of Parkinson’s symptoms. No serious adverse events occurred, and patients tolerated the rapid stimulation adjustments well.
Although larger studies are needed, the findings provide early evidence that timing stimulation to behavior may improve outcomes beyond what is possible with conventional continuous stimulation.
A New Frontier for Personalized Neuromodulation
The work represents a shift in how scientists think about brain stimulation therapies. Most aDBS systems developed to date respond to slowly changing indicators of disease state. The UCSF approach instead responds directly to behavior itself.
“This study is about more than walking,” Wang said. “It demonstrates that brain stimulation can adapt to what a person is doing in real time. That opens the door to future therapies that respond dynamically to movement, speech, mood, cognition, and other brain functions.”
Researchers envision a future in which implanted devices continuously sense and respond to neural activity, delivering personalized therapy only when and where it is needed.
“This is an important step toward a new generation of brain therapies,” said Wang. “Instead of delivering the same stimulation all day long, future devices may continuously listen to the brain and immediately respond to a patient’s needs. Just as pacemakers transformed the treatment of heart disease, intelligent neurostimulators may transform how we treat disorders of the brain.”
Additional UCSF Authors: Kenneth H. Louie, PhD, Jannine P. Balakid, BS, Jessica E. Bath, DPT, PhD, Seongmi Song, PhD, Hamid Fekri Azgomi, PhD, Jacob H. Marks, BA, Philip A. Starr, MD, PhD.
Additional Authors: Julia T. Choi, PhD, (University of Florida, Gainesville).
Funding: This study was supported by the Michael J Fox Foundation Grant MNS135499A, the UCSF Burroughs Wellcome Fund Career Award for Medical Scientist, and National Institute of Neurological Disorders and Stroke (NIH/NINDS) 1R01NS130183. This study was also partially supported by UCSF Catalyst Grants. All funding above was obtained by D.D.W.
Disclosures: D.D.W. consults for Medtronic, Boston Scientific, and Iota Bioscience, and receives research support from Boston Scientific. P.A.S. receives support from Medtronic and Boston Scientific for fellowship education. K.H.L. is a current employee of Echo Neurotechnologies. This work was completed prior to their employment at Echo Neurotechnologies, and Echo Neurotechnologies had no role in the study design, data collection, analysis, or decision to publish.
Key Questions Answered:
A: Because walking is a highly fluid, lightning-fast behavior that requires perfect, millisecond timing between the brain, spinal cord, and muscle groups on both sides of the body. Conventional DBS acts like an old-fashioned light switch, it turns on a single, un-changing stream of electricity and leaves it there all day. Because this static energy cannot adjust to the rapid, constantly shifting demands of taking individual steps, it cannot help the brain coordinate the complex mechanics of movement, leaving patients stuck in disabling freezing loops.
A: By using custom research electrodes to read the brain’s internal electrical movement signals like an open book. The UCSF team discovered that the brain generates highly specific, unique electrical patterns every single time a person intends to move their left or right leg. By mapping these custom signatures, engineers were able to program the implanted neurostimulator to recognize these step-specific signals on the fly, allowing the device to adjust its therapy to match the patient’s physical movements in real time.
A: While this study represents an absolute milestone in neural engineering, it is still in its early clinical phases. The initial trial proved the safety and mechanics of the technology across a small, highly monitored cohort of five patients. Because the device succeeded in everyday, real-world testing without any serious side effects, the medical community has an ironclad rationale to launch larger, multi-center clinical trials to gain regulatory approval, which typically takes a few years.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurotech and Parkinson’s disease research news
Author: Brooke Thornton
Source: UCSF
Contact: Siyun Qin – Brooke Thornton
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Adaptive Deep Brain Stimulation for Dynamic Gait Control in Parkinson’s 2 Disease: a randomized feasibility trial” by Kenneth H. Louie, Jannine P. Balakid, Jessica E. Bath, Seongmi Song, Hamid Fekri Azgomi, Jacob H. Marks, Julia T. Choi, Philip A. Starr & Doris D. Wang. Nature Medicine
DOI:10.1038/s41591-026-04434-2
Abstract
Adaptive Deep Brain Stimulation for Dynamic Gait Control in Parkinson’s 2 Disease: a randomized feasibility trial
A randomized crossover study of five patients with Parkinson’s disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS).
Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase.
We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle implantation were enrolled. We successfully identified personalized gait-phase biomarkers from cortical or pallidal field potentials in all five patients and embedded them into a bidirectional neurostimulator.
During acute in-clinic testing, aDBS improved step variability and step symmetry versus cDBS. Three participants subsequently completed a double-blinded, multi-day crossover phase. In this setting, aDBS maintained general motor symptom control, reduced falls and yielded patient-specific gait improvements.
No adverse events occurred and aDBS was well tolerated. These findings establish the feasibility of biomarker-driven, movement-synchronized neuromodulation and support the development of a larger randomized trial to determine clinical efficacy.
ClinicalTrial.gov registration: NCT04675398.
